ESKAZOLE

This brand name is authorized in Australia, Austria, Estonia, France, Israel, Japan, Lithuania, Malta, Mexico, Netherlands, Romania, Spain.

Active ingredients

The drug ESKAZOLE contains one active pharmaceutical ingredient (API):

1	Albendazole UNII F4216019LN - ALBENDAZOLE
	Albendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules.
	Read more about Albendazole

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
P02CA03	Albendazole	P Antiparasitic products, insecticides and repellents → P02 Anthelmintics → P02C Antinematodal agents → P02CA Benzimidazole derivatives
Discover more medicines within P02CA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8459F
EE	Ravimiamet	1146349, 1260616, 1300778, 1500387, 1736445
ES	Centro de información online de medicamentos de la AEMPS	60407
FR	Base de données publique des médicaments	68879708
IL	מִשְׂרַד הַבְּרִיאוּת	2754
JP	医薬品医療機器総合機構	6429007F1033
LT	Valstybinė vaistų kontrolės tarnyba	1076071, 1088038
MT	Medicines Authority	AA565/32402, AA729/30101
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	134M92
NL	Z-Index G-Standaard, PRK	35300
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65213002, W65213003, W65213004